Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.

× No keyword cloud information.

6 in total

1. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys.

Authors: H P Brok; J M Tekoppele; J Hakimi; J A Kerwin; E M Nijenhuis; C W De Groot; R E Bontrop; B A 't Hart
Journal: Clin Exp Immunol Date: 2001-04 Impact factor: 4.330

Review 2. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

Authors: L R Wiseman; D Faulds
Journal: Drugs Date: 1999-12 Impact factor: 9.546

Review 3. Treatment of ocular inflammation in children.

Authors: Sunil M Thadani; C Stephen Foster
Journal: Paediatr Drugs Date: 2004 Impact factor: 3.022

Review 4. Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors: Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal: Cochrane Database Syst Rev Date: 2010-01-20

5. Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation.

Authors: Hossein Saghafi; Khosrow Rahbar; Ali Nobakht Haghighi; Mohammad Qoreishi; Farshad Safdari
Journal: Nephrourol Mon Date: 2012-03-01

6. A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.

Authors: John C Mullen; Emily J Kuurstra; Antigone Oreopoulos; Michael J Bentley; Shaohua Wang
Journal: Transplant Res Date: 2014-07-30

6 in total